1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This grant aims to foster the advancement and accelerate the growth of early-career scientists transitioning to entrepreneurship by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction in areas relevant to …
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 865 -- Child Health and Human Development Extramural Research 93. 879 -- Medical Library Assistance 93.
361 -- Nursing Research 93. 350 -- National Center for Advancing Translational Sciences 93. 233 -- National Center on Sleep Disorders Research 93.
213 -- Research and Training in Complementary and Integrative Health 93. 273 -- Alcohol Research Programs 93. 837 -- Cardiovascular Diseases Research 93.
839 -- Blood Diseases and Resources Research 93. 867 -- Vision Research 93. 121 -- Oral Diseases and Disorders Research 93.
113 -- Environmental Health 93. 172 -- Human Genome Research 93. 173 -- Research Related to Deafness and Communication Disorders 93.
838 -- Lung Diseases Research 93. 279 -- Drug Abuse and Addiction Research Programs 93. 840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93.
859 -- Biomedical Research and Research Training 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research Last Updated: May 13, 2026 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) aims to facilitate the career development and transition of investigators new to entrepreneurship with an interest in small business by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction.
This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to augmenting scientific research staff and supporting research and development efforts at SBCs, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI.
Optimal PDs/PIs for this award are scientists and professionals with strong research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent research project leadership experience.
PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's mission to improve health and save lives. Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
File name Description Last updated PAR-24-133-Full-Announcement. html PAR-24-133 Full Announcement Text Apr 25, 2024 04:03 PM UTC Link to additional information https://grants. nih.
gov/grants/guide/pa-files/PAR-24-133. html Archived: November 18, 2025 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Income security and social services
According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs) led by early-career scientists transitioning to entrepreneurship. Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, and $2,045,816 for Phase II, unless proposal falls under one of the approved topics. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is funded by National Institute on Drug Abuse (NIDA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 Clinical Trial Optional) is a grant from the National Institute on Drug Abuse (NIDA) at NIH that funds small business concerns to develop science-based technologies add…
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This SBIR program aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat Substance Use Disorders (SUDs).
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article